@article{fischer_phthalimide_2025,
	title = {Phthalimide derivatives as a new class of papain‐like protease inhibitors in {SARS}‐{CoV}‐2},
	volume = {358},
	issn = {0365-6233, 1521-4184},
	url = {https://onlinelibrary.wiley.com/doi/10.1002/ardp.202400714},
	doi = {10.1002/ardp.202400714},
	abstract = {Abstract 
             
              The severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) papain‐like cysteine protease (PLpro) represents one of only two essential cysteine proteases involved in the regulation of viral replication. It, therefore, qualifies as a promising therapeutic target for the development of antiviral agents. We identified a previously synthesized protease inhibitor, resulting from an earlier project, as a PLpro inhibitor and crafted a structure–activity relationship around the hit, leading to the more potent inhibitors ZHAWOC6941 ( 
              17h 
              ) and ZHAWOC25153 ( 
              17o 
              ) displaying IC 
              50 
              values of 8 and 7 µM, respectively. The two compounds represent a new class of PLpro inhibitors and, with single‐digit micromolar IC 
              50 
              values, are comparable to inhibitors found in the literature.},
	language = {en},
	number = {1},
	urldate = {2025-06-19},
	journal = {Archiv der Pharmazie},
	author = {Fischer, Thomas and Frasson, David and Sievers, Martin and Riedl, Rainer},
	month = jan,
	year = {2025},
	pages = {e2400714},
}